Jaypirca

JAYPIRCA^® is a kinase inhibitor indicated for the treatment of:

• Adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. (
  1.1 Mantle Cell Lymphoma

  JAYPIRCA^®is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.

  This indication is approved under accelerated approval based on response rate

  [see Clinical Studies ].

  Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
  ).
  
  This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
• Adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor. (
  1.2 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  JAYPIRCA is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor.
  ).